Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer

• Status: Completed
• Trial end date: 2016-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Axitinib dose titration (giving a higher dose of the drug above its standard starting dose) among certain patients may improve the response to treatment.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Axitinib

Criteria

Inclusion Criteria:

• metastatic renal cell carcinoma (kidney cancer) with clear cell component

• no prior systemic therapy (including no prior adjuvant or neoadjuvant)

• Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1

• Blood Pressure < or = 140/90mmHg

Exclusion Criteria:

• brain/CNS metastasis

• using more than 2 blood pressure medications